longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Inhibrx Biosciences

INBX

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Q2 FY2026 Earnings

Financial report interval: 2026.03.30 - 2026.06.30

Overview: Inhibrx Biosciences(INBX) the EBIT is -32.15 M (-17.38%), Beat estimate;the EPS is -2.34 (-26.49%), Beat estimate.

Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B100.00%
----
EBITExceed expectations
-0.03B17.38%
-0.03B27.60%
+0.00B10.22%
EPSExceed expectations
-2.3426.49%
-2.3929.19%
+0.05002.70%

Revenue

ActualEstimateUnit: USD
qf

EBIT

ActualEstimateUnit: USD
qf

Net income

ActualEstimateUnit: USD
qf

EPS

ActualEstimateUnit: USD
qf